Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:55:34 EST Fri 23 Jan 2026
Enter Symbol
or Name
USA
CA



Z:IGC - IGC PHARMA INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IGC - Z0.10.2706·1.004.20.291-0.0121-4.0253.5634010.31  0.31  0.2880.4985  0.252519:45:12Jan 2215 min RT 2¢

Recent Trades - Last 10 of 401
Time ETExPriceChangeVolume
19:45:12Z0.2958-0.0053100
19:35:31Z0.29-0.011113
19:07:11Z0.29-0.0111209
18:58:06Z0.2939-0.00724
18:54:28Z0.2939-0.00721
18:52:12Z0.29-0.0111100
18:41:09Z0.2918-0.00935
18:38:49Z0.2918-0.0093100
18:30:14Z0.2978-0.00332
18:24:40Z0.2927-0.00841

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-22 09:00U:IGCNews ReleaseIGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
2026-01-12 09:00U:IGCNews ReleaseIGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia
2026-01-06 08:00U:IGCNews ReleaseIGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
2026-01-05 09:00U:IGCNews ReleaseIGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
2025-12-19 09:00U:IGCNews ReleaseIGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum
2025-12-15 09:00U:IGCNews ReleaseIGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines
2025-12-10 09:00U:IGCNews ReleaseIGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."
2025-12-09 09:00U:IGCNews ReleaseIGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
2025-12-02 09:00U:IGCNews ReleaseIGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease
2025-11-25 09:00U:IGCNews ReleaseIGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends
2025-11-17 08:30U:IGCNews ReleaseIGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital
2025-11-13 09:00U:IGCNews ReleaseUSPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders
2025-11-10 09:00U:IGCNews ReleaseIGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025
2025-11-03 08:53U:IGCNews ReleaseIGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline
2025-10-22 09:00U:IGCNews ReleaseIGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"
2025-10-14 09:00U:IGCNews ReleaseIGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences
2025-10-10 19:51U:IGCNews ReleaseIGC Pharma Announces Results of 2025 Annual Meeting of Stockholders
2025-10-07 09:00U:IGCNews ReleaseIGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease
2025-09-29 09:00U:IGCNews ReleaseIGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial
2025-09-24 09:00U:IGCNews ReleaseIGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology